Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369492 | 0.94 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6365203 | 0.81 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6364445 | 0.78 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6364794 | 0.78 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6365131 | 0.78 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5878607 | 0.74 | SLC6A4 (0.80) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5878517 | 0.74 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6276352 | 0.72 | KDM4C (0.45) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL24047163 | 0.71 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6370115 | 0.70 | FTO (0.47) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800652-B2 | SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER INC. | 2004-10-05 | — | — | US | claimed |
| US-20040097509-A1 | Diaryl compounds | PFIZER INC. | 2004-05-20 | — | — | US | claimed |
| US-20050026920-A1 | Selective serotonin re-uptake inhibitors; use in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders and sexual dysfunction | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| US-6800652-B2 | SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER INC. | 2004-10-05 | — | — | US | disclosed |
| US-20040097509-A1 | Diaryl compounds | PFIZER INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097509-A1 | Diaryl compounds | CCNL2, CCNI, CCNA1 | SLC6A4 1969/4885SLC6A2 1307/4885SLC6A3 1978/4885 |
| US-20050026920-A1 | Selective serotonin re-uptake inhibitors; use in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders and sexual dysfunction | SLC6A4, SLC6A2, SLC6A3 | SLC6A4 1/4885SLC6A2 2/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.